Exagen Inc. To Participate in 2021 ICR Conference
January 05 2021 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, announced today that company management will
participate in the 2021 ICR Conference, which takes place January
11-14, 2021. Ron Rocca, Exagen’s President and Chief Executive
Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will
participate in a virtual fireside chat on Thursday, January 14 at
11:30 AM ET, which is accessible to conference attendees.
Management will also be participating in one-on-one meetings with
investors during the event; meetings can be requested through the
ICR Conference site.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune related diseases, including
rheumatoid arthritis and lupus. For further information, please
visit www.exagen.com.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
company’s current beliefs and expectations. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Exagen’s business, including, without limitation: the COVID-19
pandemic may continue to adversely affect our business, financial
condition and results of operations, including as a result of
shutdowns of our facilities and operations as well as those of our
suppliers and courier services, impeding patient movement and
interruptions to healthcare services causing a decrease in test
volumes, disruptions to the supply chain of material needed for our
tests, our sales and commercialization activities and our ability
to receive specimens and perform or deliver the results from our
tests, delays in reimbursement and coverage decisions from Medicare
and third-party payors and in interactions with regulatory
authorities, and delays in ongoing and planned clinical trials
involving our tests; the company’s commercial success depends upon
attaining and maintaining significant market acceptance of its
testing products and promoted therapeutics among rheumatologists,
patients, third-party payers and others in the medical community;
the company’s ability to successfully execute on its Dx/Rx
strategy, including its promotion efforts for SIMPONI®; third party
payers not providing coverage and adequate reimbursement for the
company’s testing products or promoted therapeutics; the company’s
ability to obtain and maintain intellectual property protection for
its testing products; regulatory developments affecting the
company’s business; and other risks described in the company’s
prior press releases and the Company’s filings with
the Securities and Exchange Commission (SEC), including
under the heading “Risk Factors” in the company’s Annual Report on
Form 10-K and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com 646.677.1838
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024